These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 37625842)
41. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells. Tang C; Luo H; Luo D; Yang H; Zhou X Oncol Rep; 2018 Feb; 39(2):611-618. PubMed ID: 29207183 [TBL] [Abstract][Full Text] [Related]
44. Development of a biotin-streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRAS Liu S; Shi J; Li H; Li J; Zhu Y; Li B; Sun Y SLAS Discov; 2022 Mar; 27(2):107-113. PubMed ID: 35058184 [TBL] [Abstract][Full Text] [Related]
45. Targeting KRAS in Colorectal Cancer. Wang C; Fakih M Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927 [TBL] [Abstract][Full Text] [Related]
46. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction. Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726 [TBL] [Abstract][Full Text] [Related]
47. Low-grade slightly elevated and polypoid colorectal adenomas display differential β-catenin-TCF/LEF activity, c-Myc, and cyclin D1 expression. Yang TW; Gao YH; Ma SY; Wu Q; Li ZF World J Gastroenterol; 2017 May; 23(17):3066-3076. PubMed ID: 28533663 [TBL] [Abstract][Full Text] [Related]
48. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138 [TBL] [Abstract][Full Text] [Related]
49. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620 [TBL] [Abstract][Full Text] [Related]
50. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors. Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229 [TBL] [Abstract][Full Text] [Related]
52. Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting. Yaeger R; Solit DB Clin Cancer Res; 2020 Apr; 26(7):1538-1540. PubMed ID: 32001483 [TBL] [Abstract][Full Text] [Related]
53. Glimmers of hope for targeting oncogenic KRAS-G12D. Tang D; Kang R Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681 [TBL] [Abstract][Full Text] [Related]
54. Landscape of Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967 [TBL] [Abstract][Full Text] [Related]
55. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors. Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384 [TBL] [Abstract][Full Text] [Related]
56. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640 [TBL] [Abstract][Full Text] [Related]
57. Synthesis of Chen CY; Lu Z; Scattolin T; Chen C; Gan Y; McLaughlin M Org Lett; 2023 Feb; 25(6):944-949. PubMed ID: 36723667 [TBL] [Abstract][Full Text] [Related]